Precision Optics Stock Price, News & Analysis

Precision Optics (NASDAQ: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has appointed Joseph P. 'JJ' Pellegrino, Jr. to its Board of Directors. Pellegrino will serve as Chairman of the Board's Audit Committee.

Pellegrino brings significant experience from his recent role as CFO of LeMaitre Vascular (2007-2025), where he continues as a board member. His career includes positions as Executive VP of Finance at LeMaitre, SVP of Operations at Zoots, and investment banking analyst at Lehman Brothers. He holds degrees from Harvard College and Harvard Business School.

The appointment coincides with Peter Anania's retirement from the Board, who joined in October 2021 following Precision Optics' acquisition of Lighthouse Imaging, where he served as President and Chairman.

Precision Optics (NASDAQ: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has announced key changes to its Board of Directors. Buell Duncan, former Chief Marketing Officer of IBM Software, Cloud, Data and AI businesses, has been appointed to the board, bringing extensive executive leadership experience from his 28-year tenure at IBM (1992-2020).

Duncan currently serves as a Portfolio Advisor and Partner with Iron Gate Capital, a venture capital firm focused on early-growth B2B technology companies. He is also a Board observer of SHARE Mobility and Respondology, and a Strategic Advisor to several technology companies.

Concurrent with Duncan's appointment, Dr. Richard Miles, who joined the board in November 2005, has announced his retirement after nearly 20 years of service.

Precision Optics (NASDAQ: POCI) has successfully closed a registered direct offering of common stock, raising $5.1 million in gross proceeds through the sale of 1,272,500 shares at $4.00 per share. The company expects net proceeds of approximately $5.0 million after deducting offering expenses.

The funds will be allocated to three main purposes: repaying certain indebtedness, expanding facilities to support anticipated growth, and general working capital. The offering was conducted under an effective shelf registration statement on Form S-3, which was declared effective on June 14, 2024, with a prospectus supplement filed on February 20, 2025.

Precision Optics (NASDAQ: POCI) has announced a registered direct offering of 1,272,500 shares of common stock at $4.00 per share, expected to generate gross proceeds of approximately $5.1 million and net proceeds of about $5.0 million after expenses.

The offering, led by existing stockholders, is scheduled to close around February 21, 2025. The company plans to use the proceeds to repay certain debts, expand facilities to support growth, and for general working capital purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 previously filed with the SEC.

Precision Optics (NASDAQ: POCI) reported Q2 FY2025 results with revenue of $4.5 million, down from $4.8 million year-over-year but up 8% sequentially. Production revenue increased 42% sequentially to $3.3 million, while engineering revenue decreased to $1.2 million. The company reported a net loss of $1.0 million and adjusted EBITDA of -$0.6 million.

Gross margins declined to 23.6% from 30.1% in the same quarter last year. Notable developments include the January 2025 launch of the Unity Imaging Platform for endoscopic imaging devices, and receipt of a $340,000 production order for ophthalmic endoscopes. The company is accelerating deliveries against a $9 million order for urological endoscope imaging assemblies, with expected deliveries of $2.7 million in fiscal year 2025.

Precision Optics (Nasdaq: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has scheduled a conference call to discuss its second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET.

The company will release its financial results and file its 10-Q after market close on the same day. Interested parties can join via phone at (844) 735-3662 or (412) 317-5705, or through a live webcast at https://app.webinar.net/z0E94DknxQO. A seven-day replay will be available through phone and webcast.

Precision Optics (Nasdaq: POCI) has launched the Unity Imaging Platform, a standardized CMOS endoscopic system with customization options for medical, industrial, and defense applications. The platform represents a significant shift from traditional custom-built solutions, offering a modular architecture suitable for both reusable and single-use endoscopic systems.

The Unity platform aims to transform endoscopic imaging device development by reducing costs, development time, and project risks through pre-validated design elements and proven architectures. Key benefits include accelerated time to market, cost efficiency, risk mitigation, and scalability for product portfolios.

The company currently has two single-use endoscope programs in production, with more in development. Future platform expansions will include advanced capabilities such as multi-sensor imaging for 3D and fluorescence applications.

Precision Optics (POCI) has received a $340,000 initial production order for a new single-use ophthalmic endoscope from a major global medical device company. Production will start in January 2025, with delivery over five months to support a June 2025 product launch. Follow-on orders are expected at 2-3x the initial rate. This represents the second single-use program moving to production this year, following a $9 million cystoscope imaging assembly order. The new product replaces an existing reusable endoscope system with improved image quality and single-use functionality.

Precision Optics (NASDAQ: POCI) reported Q1 FY2025 financial results with revenue of $4.2 million, slightly down from $4.3 million in Q1 FY2024. The company experienced decreased gross margins of 26.6% compared to 33.9% year-over-year, and reported a net loss of $1.3 million. Engineering revenue remained stable at $1.9 million, while production revenue slightly decreased to $2.3 million. Notable developments include accelerated production deliveries for a $9 million urological endoscope order and a new $340,000 production order for single-use ophthalmic endoscopes, with expectations of substantial revenue growth in Q2 FY2025.